NEW YORK – ObjectiveHealth on Tuesday said it has partnered with Urology of St. Louis to study urologic disorders in a new research program that includes interventional clinical trials with a focus on predictive biomarkers.
A joint clinical research center, Specialty Clinic Research of St. Louis, will be home to the collaboration, offering access to diagnostic tools and treatments in urologic diseases including bladder and prostate cancer.
Nashville, Tennessee-based ObjectiveHealth is a provider of integrated research services for physicians and healthcare organizations. It has partnered with over 30 programs in 16 US states and offers a suite of tools to identify and prequalify patients for trials, track patient data in real time, and manage care for patients not yet enrolled in a trial.
"We're proud to offer access to more treatment options for urology patients through our new partnership with Urology of St. Louis," ObjectiveHealth CEO Colleen Hoke said in a statement. "By contributing to the growing body of research surrounding urological diseases, we hope to help improve the standard of care for those affected."